YORBA LINDA, Calif. (PRWEB) November 26, 2018
By enabling the detection of single-cell phenotypes after small molecule or biological perturbation, high-throughput confocal microscopy has changed the way drug screening can be performed. Combined with advances in image analysis, which have allowed for the quantification of these single cell events, it opens new doors for large phenotype-focused studies. However, these technologies have historically been used with adherent cell lines. By amending these technologies to non-adherent cells, we can perform image-based screening directly in human primary material, enabling more clinically translatable drug screening, and ultimately, functional precision medicine.
Dr. Gregory Vladimer, the speaker for this event, is the CSO and Scientific Co-Founder of Allcyte in Vienna, Austria. Greg received his PhD in immunology from the Program in Innate Immunity of the Department of Medicine at the University of Massachusetts Medical School, prior to his postdoctoral work at the Center for Molecular Medicine of the Austrian Academy of Sciences.
During the presentation, he will discuss the interim results of a clinical trial, from the Center of Molecular Medicine of the Austrian Academy of Sciences and the Medical University of Vienna, which combined multiparametric immunofluorescence with high-throughput automated microscopy and single cell image analysis with the aim to quantify tumor-cell specific biological parameters of millions of adherent and non-adherent individual cells from primary samples. This resulted in the ability to prioritize treatment options for patients with late-stage hematological malignancies. An interim analysis, published in late 2017 Lancet Haematology, revealed that patients receiving treatment prioritized by this program had a longer progression-free survival on this therapy than the prior round of therapy.
This style screening can be further combined with epigenetic sequencing to rationally uncover combination treatment options for specific indications. Lastly, using images of multi-lineage cells from the haematological system, and novel statistical algorithms, we can quantify the propensity of cells to physically interact with each other, thereby mapping the effect of ex vivo stimuli on immune responses, and potentially uncover new immunomodulatory drugs.
Join this free webinar on December 6, 2018, beginning at 15:00 GMT, 16:00 CET, 10:00 EST, 07:00 PST. To learn more about this event, the continuing education credits offered, or to register click here.
PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.3 billion in 2017, has about 11,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE.
LabRoots is the leading scientific social networking website, offering top scientific trending news and premier educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning. We have become a primary source for trending scientific news, webinars, virtual conferences and more. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, LabRoots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events. Join for free and become part of the largest scientific learning community in the world.
Allcyte is a start-up biotechnology company located in Vienna, Austria focusing on the use of
high-throughput and high-content automated confocal imaging of primary patient material
to answer key biological questions of drug function and action – and progressing function drug testing and “big-data imaging” for precision cancer medicine. Allcyte is a spin-off of CeMM, the Center for Molecular Medicine of the Austrian Academy of Sciences.